NCT06561152 2026-04-14Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLStanford UniversityPhase 1/2 Recruiting20 enrolled
NCT07148180 2026-02-05A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxDana-Farber Cancer InstitutePhase 1/2 Recruiting31 enrolled